The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis

被引：0
|
作者：
Deodhar, Atul
Mease, Philip
Machado, Paula
Pournara, Effie
Meng, Xiangyi
Strand, Vibeke
Magrey, Marina
机构：
来源：
ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷
关键词：
EFFICACY; SAFETY;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0350
引用
收藏
页数：4
相关论文
共 50 条
  • [41] SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, MEASURE 2
    Baraliakos, X.
    Schiff, M.
    Pavelka, K.
    Widmer, A.
    Porter, B.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 358 - 358
  • [42] NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS FROM THE MEASURE 2, 3 AND 4 PHASE 3 TRIALS
    Dougados, M.
    Kiltz, U.
    Kivitz, A.
    Pavelka, K.
    Rohrer, S.
    Mccreddin, S.
    Quebe-Fehling, E.
    Porter, B.
    Talloczy, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 415 - 416
  • [43] Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
    Coates, Laura
    McInnes, Iain
    Husni, M. Elaine
    Vizcaya, Cynthia
    Bao, Weibin
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1200 - 1203
  • [44] Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing
    Braun, Juergen
    Deodhar, Atul A.
    Sieper, Joachim
    Dougados, Maxime
    Porter, Brian
    Andersson, Mats
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [45] Pooled fezolinetant safety data over 52 weeks from three randomized Phase 3 studies (SKYLIGHT 1, 2 and 4)
    Kagan, Risa
    Cano, Antonio
    Nappi, Rossella
    English, Marci
    Valluri, Udaya
    Ottery, Faith D.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2023, 30 (12): : 1281 - 1281
  • [46] BIMEKIZUMAB ACHIEVED SUSTAINED IMPROVEMENTS IN EFFICACY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, REGARDLESS OF PRIOR TNF INHIBITOR TREATMENT: WEEK 52 POOLED RESULTS FROM TWO PHASE 3 STUDIES
    Magrey, M.
    Van de Sande, M. G. H.
    Breban, M.
    Van den Bosch, F.
    Fleurinck, C.
    Massow, U.
    De Peyrecave, N.
    Vaux, T.
    Baraliakos, X.
    Marzo-Ortega, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 876 - 877
  • [47] Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
    Magrey, Marina Nighat
    van de Sande, Marleen
    Breban, Maxime
    Van den Bosch, Filip
    Fleurinck, Carmen
    Massow, Ute
    De Peyrecave, Natasha
    Vaux, Thomas
    Baraliakos, Xenofon
    Marzo-Ortega, Helena
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1030 - 1032
  • [48] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN ANTI-TNF-NAIVE PATIENTS AND THOSE PREVIOUSLY EXPOSED TOANTI-TNF THERAPY: 52-WEEK RESULTS FROM TWO INTERNATIONAL PHASE 3 TRIALS
    Deodhar, Atul
    Baeten, Dominique
    Blanco, Ricardo
    Sieper, Joachim
    Martin, Ruvie
    Porter, Brian
    Richards, Hanno
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 137 - 138
  • [49] Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled "Post Hoc" Analysis from Five Phase 3 Studies
    Felten, Renaud
    Widawski, Laura
    Spielmann, Lionel
    Gaillez, Corine
    Bao, Weibin
    O'Neill, Hugh
    Gottenberg, Jacques-Eric
    Duret, Pierre-Marie
    Messer, Laurent
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1988 - 1991
  • [50] Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial
    Baraliakos, Xenofon
    Schiff, Michael
    Pavelka, Karel
    Martin, Ruvie
    Porter, Brian
    Gaillez, Corine
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345